NEW YORK (GenomeWeb) – Dako, an Agilent subsidiary, has declared CE Mark self-certification for its PD-L1 IHC 22C3 pharmDx, a companion diagnostic to identify best responders to Merck's anti-PD-1 immunotherapy Keytruda (pembrolizumab).

Dako developed the PD-L1 IHC 22C3 pharmDx test in partnership with Merck. By affixing a CE Marking on a product, the manufacturer is declaring that it is in conformity with EU legislation and requirements and can now be sold throughout the European Economic Area.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Jul
10
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.